// App-Quantinova.ai

ABS112 : FACTOR UTILISATION IN PATIENTS WITH HAEMOPHILIA A AFTER SWITCHING TO RURIOCTOCOG ALFA PEGOL IN THE ATHN 2 STUDY

Researchers

Presenter

  • J. Journeycake

Principal Investigators

  • J. Caicedo

  • D. Cheng

  • M. Denne

  • C. Guelcher

  • S. Lattimore

  • A. Mokdad

  • M. Ragni

  • M. Recht

  • R. Sidonio,Jr

  • C. Takemoto

  • M. D. Tarantino

  • C. Watson

  • E. Neufeld

Medical Centers

  • University of Oklahoma School of Medicine, Oklahoma City, OK

  • Takeda, Cambridge, MA

  • American Thrombosis and Hemostasis Network, Rochester, NY

  • Children National Hospital, Washington, DC

  • Oregon Health and Science University, Portland, OR

  • Universityof Pittsburgh and the Haemophilia Center of WesternPennsylvania, Pittsburgh, PA, United States

  • Emory University, Aflac Cancer and Blood Disorders, ATLANTA, GA

  • St. Jude Children's Research Hospital, Memphis, TN

  • The Bleeding and Clotting Disorders Institute,Peoria IL,United States;University of Illinois College of Medicine-Peoria,Peoria IL,United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Hemophilia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rurioctocog alfa

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • American Thrombosis And Hemostasis Network (ATHN)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved